Fingolimod-Associated Intracerebral Lymphoproliferative Disorder.
Am J Ther
; 26(4): e481-e484, 2019.
Article
em En
| MEDLINE
| ID: mdl-29189316
ABSTRACT
Most epidemiological studies indicate that incidence of cancer in multiple sclerosis patients is lower than general population. However these studies were performed prior to the emergence of disease-modifying therapies (DMTs). The incidence of cancer may be influenced by newer generation DMTs which are immunomodulatory or immunosuppressant. We describe an atypical case of intracerebral plasmacytic lymphoproliferative disorder in a 47 years old patient on fingolimod. As worldwide usage of oral and infusion DMTs increases, heightened clinical suspicion and early recognition of these serious adverse events remain crucial.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Leucemia Plasmocitária
/
Cloridrato de Fingolimode
/
Imunossupressores
/
Esclerose Múltipla
Tipo de estudo:
Risk_factors_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article